Cephalon to acquire Mepha AG

Cephalon, Inc. has signed an agreement to acquire Mepha AG and its subsidiaries for $590 million.

The privately-held, Swiss-based Mepha is focused on innovative dosage formulations for both generic and branded products.The acquisition doubles the size of Cephalon’s international business and provides a platform to launch current and future products in developed and emerging markets.

Mepha manufactures and markets more than 120 products in 50 countries and has a pipeline of approximately 50 chemical entities planned for launch during the next five years.

[Contract Pharma]